<DOC>
	<DOCNO>NCT00587249</DOCNO>
	<brief_summary>The purpose study evaluate safety immune response ( body 's defense system ) investigational malaria vaccine call ICC-1132 . Three different dos vaccine study 3 group people , result compare . The study involve 80 healthy volunteer , 18-45 year age , receive injection specific dose vaccine arm 2 3 different day . Blood sample collect approximately 15 time laboratory study . Volunteers record temperature twice per day . Volunteers complete daily symptom diary 7 day vaccination . Volunteers participate study 13 month .</brief_summary>
	<brief_title>ICC-1132 - Candidate Vaccine Against P Falciparum Malaria</brief_title>
	<detailed_description>This Phase I , dose-escalating clinical trial candidate malaria vaccine , ICC-1132 . The primary objective ass compare safety , reactogenicity , immunogenicity 3 intramuscular injection ICC-1132 . The vaccine absorb alhydrogel adjuvant . Three dose level , 10 mcg , 20 mcg , 50 mcg , compare . Vaccine inject intramuscularly study day 0 , 56 +/- 4 168 +/- 14 , exception 10 mcg dose cohort receive 2 injection , 1 0 2 month . The study originally design blind , dose-escalating trial compare 3 dos ( 10 , 20 , 50 mcg ) ICC-1132 saline 3 dose ICC-1132 + alhydrogel ( 10 , 20 , 50 mcg ) . Prior remove saline formulate ICC-1132 trial , first 16 eligible volunteer assign 10 mcg cohort , 8 receive ICC-1132 saline 8 receive ICC-1132 + alhydrogel . The next 3 eligible volunteer assign 20 mcg cohort randomly assign receive ICC-1132 saline ICC-1132 + alhydrogel . The study continue vaccination use alhydrogel formulation vaccine . Subjects observed immediate localize systemic reaction 30 minute release clinic . Vital sign post-vaccination arm check perform approximately 30 minute vaccine administration . Subjects return outpatient clinic clinical examination 24 +/- 6 48 +/- 6 hour , day 7 +/- 1 , 14 +/- 2 , 28 +/- 4 vaccination . Volunteers complete daily symptom diary 7 day vaccination . Additional follow visit do 84 +/- 7 day second vaccine 56 +/- 7 day third vaccine . A telephone interview do day 4 +/- 1 immunization 168 +/- 14 day third immunization . Participants involve study related procedure 393 day .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Male female 18 45 year age . Willingness participate study evidence sign , write informed consent . An informed consent write exam score least 70 % . If female , willingness avoid pregnancy practice adequate birth control time study enrollment least 2 month third vaccination . Agrees refrain blood donation course study . Agrees available schedule study visit ( vaccination followup ) . Agrees participate concurrent vaccine drug trial evaluate Apovia 's ICC1132 . Evidence renal disease , indicate following : Creatinine &gt; 1.5 mg/dL within 7 day first vaccination RBC WBC cast urine Urine protein great equal 1 plus urinalysis Evidence cardiovascular disease , indicate following : BP &gt; 150/90 mmHg two measurement different day Hospitalization heart attack , arrhythmia , syncope Murmur ( functional murmur ) detect physical examination History cancer ( except basal call carcinoma skin cervical carcinoma situ ) Evidence liver reticuloendothelial disease , indicate following : Positive serology hepatitis B surface antigen Positive serology hepatitis C antibody AST ALT 1.5 time normal within 7 day first vaccination Hepatosplenomegaly , jaundice , lymphadenopathy physical examination Evidence neurological disease , indicate following : History seizure ( febrile seizure child &lt; 5 year old ) History unconsciousness ( single brief `` concussion '' ) Recurrent severe headache diagnosis migraine headache Focal neurological deficit physical examination suggest pathologic process Evidence gastrointestinal disease , indicate following : Recurrent diarrhea ( &gt; 5 episode past 6 month , last least 3 day , least one week episode ) Frequent indigestion heartburn require daily antacid medical therapy Diagnosed doctor uncontrolled irritable bowel syndrome , Crohn 's disease , ulcerative colitis , celiac disease , stomach intestinal ulcer Blood stool past year ( occasional small amount strain hemorrhoid ) Evidence hematologic , rheumatologic , immunologic disease , indicate following : WBC &lt; 3.0 x 10^3/mm^3 &gt; 13.5 x 10^3/ mm^3 within 7 day first vaccination Absolute neutraophil count &lt; 1500/ mm^3 within 7 day first vaccination Hemoglobin ( within 7 day first vaccination ) Females &lt; 10.5 g/dL &gt; 18 g/dL Males &lt; 11.5 g/dL &gt; 20 g/dL History great equal 2 hospitalization invasive bacterial infection ( pneumonia , meningitis ) History hemoglobinopathy sickle cell disease thalassemia Diagnosis collagen vascular disease lupus dermatomyositis Positive serology HIV antibody History diabetes mellitus 3hour fast blood glucose &gt; 125 mg/dL Evidence pulmonary disease indicate follow : History asthma require use oral medication meter dose inhaler previous 12 month Wheezes , rales , prolonged expiratory phase auscultation lung Is required take daily medication vitamin , levothyroxine , birth control pill , hormone replacement therapy menopause , follow medication attention deficit hyperactivity disorder ( pemoline [ Cylert ] , methylphenidate HC1 [ Ritalin , RitalinSR , Concerta ] , dextroamphetamine sulfate [ Dexedrine , Adderall ] , bupropion HC1 [ Wellbutrin , WellbutrinSR ] ) Receives allergy shot use allergy medication chronically Behavioral , cognitive , psychiatric disease opinion investigator affect ability volunteer understand cooperate study protocol Volunteer medical , occupational , family problem result alcohol illicit drug use past 12 month Pregnancy ( positive urine pregnancy test immediately prior dose , positive serum pregnancy test screen ) breastfeed Temperature &gt; 38 degree C ( 100.4 degree F ) symptoms acute selflimited illness upper respiratory infection gastroenteritis vaccination day ; subject may reschedule enter trial illness resolve , per protocol Use investigational drug , product device within 30 day prior study drug administration Vaccination live vaccine within 30 day kill vaccine within 2 week History malaria infection vaccination candidate malaria vaccine Allergy aminoglycosides , tetracycline , related antibiotic gentamicin , kanamycin doxycycline Weight le 110 pound Other condition opinion investigator would jeopardize safety right volunteer participate trial would render subject unable comply protocol History immediatetype hypersensitivity reaction vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Malaria , Plasmodium falciparium , Hepatitis B Core Antigen , Circumsporozoite Epitopes</keyword>
</DOC>